Accueil / Communiqués / Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

Wednesday, February 27th 2019 at 12:00pm UTC

SEATTLE–(BUSINESS WIRE)– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage
immunotherapy company focused on developing innovative treatments for
cancer, autoimmune/inflammatory, and other diseases, today announced the
company will participate in two upcoming investor conferences in March.

Cowen and Company 39th Annual Health Care Conference
Tuesday, March 12, 2019
Time: 9:20 a.m. Eastern Time
Boston, MA

Oppenheimer 29th Annual Healthcare Conference – Analyst-Led Fireside

Date: Tuesday, March 19, 2019
Time: 1:35 p.m. Eastern
Location: New York, NY

A live webcast of each presentation will be available online in the
investor relations section of the company’s website at
A replay of the presentations will be available on the company website
for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of
functional immune therapeutics. Alpine is employing directed evolution
to create potentially powerful multifunctional immunotherapies to
improve patients’ lives. Alpine has two lead programs. The first,
ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28
antagonist, engineered to reduce pathogenic immune responses. ALPN-101
is in a Phase I healthy volunteer trial with data expected to be
reported later in 2019. The second, ALPN-202 for cancer, is a dual
PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended
to combine checkpoint inhibition with T cell costimulation – an approach
currently absent from approved checkpoint therapies. Alpine is backed by
world-class research and development capabilities, a highly-productive
scientific platform, and a proven management team. For more information,


Investor Relations:
Pure Communications
Courtney Dugan,

Media Relations:
Pure Communications
Jennifer Paganelli,

Source: Alpine Immune Sciences, Inc.

Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …